PROCEPT BioRobotics Corp. (PRCT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$22.76+6.50%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · PRCT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -9.8% |
| Our one-year growth estimate | diamond | 29.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 39.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
PRCT — earnings in line
Dated 2026-08-04
Results of Operations and Financial Condition On August 4, 2026 , PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2026 . The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities…
Why it matters: Faster growth in the sector may help PROCEPT's market position and increase revenue.
Watch forHealth Care sector revenue growth reported above 10% year over year.
Also watch forHealth Care sector revenue growth reported below 5% year over year.
Why it matters: A bigger loss shows problems with controlling costs and making profits.
Worry ifAdjusted EBITDA loss was over $30 million for Q2.
Less concerning ifAdjusted EBITDA loss reported at or below $30 million for Q2.
Why it matters: A drop below median growth could signal weakening in the health care sector overall.
Worry ifSector revenue growth reported below its median.
Less concerning ifSector revenue growth stays above its median.
Why it matters: Achieving this revenue range is key for long-term growth. It reflects market demand for products.
Supportive ifTotal revenue reported between $390 million and $410 million for the full year 2026.
Worry ifTotal revenue reported below $390 million for the full year 2026.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$262 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $559 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,897 loss on $10,000 · 59.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: News about this trial can change future products and market position.
Watch forGood news or milestones from the WATER IV trial.
Also watch forNegative updates or delays in the WATER IV trial.
Why it matters: Keeping this margin shows the company is controlling costs while growing. It shows efficiency.
Supportive ifGross margin remains at or above 65% for the full year 2026.
Worry ifGross margin drops below 65% for the full year 2026.
Why it matters: A drop would make it hard for the company to manage costs and profits.
Worry ifGross margin reported below 65% for Q2.
Less concerning ifGross margin reported at or above 65% for Q2.
Why it matters: Strong growth in other countries helps meet revenue goals and expand markets.
Supportive ifInternational revenue growth exceeds 15% year over year in Q3 2026.
Worry ifInternational revenue growth falls below 15% year over year in Q3 2026.
Why it matters: More advancements could improve the product and boost sales.
Supportive ifThere was an announcement of more FDA clearances for FirstAssist AI software.
Worry ifNo updates or delays in FDA approvals for FirstAssist AI software.
Why it matters: This shows sales are slowing down. It will affect full-year targets.
Worry ifQ2 revenue growth reported below 20% year over year.
Less concerning ifQ2 revenue growth reported at or above 20% year over year.
Why it matters: This change shows the company is getting closer to making money. It shows better cost control.
Supportive ifAdjusted EBITDA loss narrows to $35 million or less by year-end 2026.
Worry ifAdjusted EBITDA loss will be more than $35 million by the end of 2026.
Why it matters: This volume target shows how well the company is growing its business. Meeting this goal signals strong demand for its products.
Supportive ifU.S. procedure volume reaches 54,000 or higher by year-end 2026.
Worry ifU.S. procedure volume falls below 54,000 by year-end 2026.